Discovery in the NCI-MATCH precision medicine cancer trial is consistent with another recent trial, signaling that the data on ado-trastuzumab (T-DM1) is promising for this rare cancer ECOG-ACRIN CANCER RESEARCH GROUP The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology....